May 21, 2019- Late-breaking data for Abbott's investigational clip-based tricuspid heart valve repair system presented at EuroPCR- Data suggest the first-of-its-kind device reduces difficult-to-treat tricuspid regurgitation at 30 days- Study builds upon Abbott's success with its proven MitraClip™ clip-based technology in treating a similar disease on the left side of the heart- May 14, 2019- Partnership with NIH aims to increase understanding and accelerate the application of neurostimulation therapies- The BRAIN Initiative brings together the brightest minds across disciplines to improve the treatment and prevention of brain disorders
- Apr 29, 2019- Research found Abbott's High-Sensitive Troponin-I blood test may identify adults at risk of having a cardiac event, independent of other heart disease risk factors- Abbott's core laboratory diagnostic test is the first troponin blood test with CE Mark that can more accurately predict risk of developing heart disease, when added to other heart disease risk assessments, than using other assessments alone
- Mar 14, 2019- The world's first minimally invasive mitral valve repair device now approved to help difficult-to-treat heart failure patients with clinically significant secondary mitral regurgitation- Approval is based on groundbreaking pivotal data from the COAPT™ Trial- New indication significantly expands number of people with mitral regurgitation that can be treated with the MitraClip device
- Feb 20, 2019Collaboration will enable insulin data to be shared between Novo Nordisk connected insulin pens and digital health tools compatible(i) with FreeStyle Libre portfolio of products
- Jan 21, 2019With approval of the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™, Abbott is helping more physicians integrate ablation with 3D mapping to advance the treatment of people with atrial fibrillation
-
Jan 19, 2019- Data from two recent studies presented at NANS 2019 demonstrate key benefits of BurstDR™ stimulation- Microdosing BurstDR stimulation at lowest effective energy allows patients to manage their pain without the burden of recharging their devices- Additional data further showed switching from other types of SCS therapies to Abbott’s BurstDR stimulation significantly reduced pain and the need for opioid medication
-
Nov 15, 2018New White Paper Shares Research Findings on Perceptions and Awareness of Medical Device Cybersecurity, Need for Collaboration to Address Cybersecurity Challenges
-
Oct 25, 2018NEW ASSAYS EMPOWER CLINICIANS TO MORE QUICKLY MAKE THE RIGHT DIAGNOSIS AT THE POINT-OF-CARE AND PRESCRIBE THE RIGHT TREATMENT
-
Oct 17, 2018PRELIMINARY RESEARCH INDICATES THAT A DIAGNOSTIC TEST CURRENTLY IN DEVELOPMENT, THAT IS DONE AT THE PATIENT'S SIDE IN MINUTES, HAS SIMILAR ACCURACY TO A HIGH-SENSITIVE TROPONIN TEST FOR EARLY RULE OUT OF A HEART ATTACK
-
May 22, 2018- Data presented at EuroPCR indicated excellent clinical outcomes for Portico in a real-world setting to treat common and life-threatening heart valve disease with minimally invasive option- Portico is the first fully resheathable, repositionable and retrievable device – now with a sheathless delivery option – to replace a diseased or damaged aortic heart valve without major surgery- Data are consistent with earlier study results used to support CE Mark
-
Apr 11, 2018- Largest-ever randomized trial to evaluate superiority of light-based, three-dimensional imaging (optical coherence tomography (OCT)) versus X-ray-based angiography in patients with complex coronary artery disease who receive a stent- Trial will assess if stent procedures guided by high-resolution imaging result in larger vessel diameters and improved patient clinical outcomes versus stent procedures that use standard-of-care imaging- Use of OCT imaging may help doctors be more precise in stent implantation
- Mar 6, 2018- First and only pediatric mechanical heart valve developed to include newborns and infants- Life-saving technology - the size of a dime - provides new treatment option to address unmet need- Nearly one in four children with critical heart defects may require surgery or other procedures in their first year of life[1]
-
Oct 11, 2017- A new dataset published in The Lancet: Psychiatry highlights the largest prospective study in DBS for chronic, treatment-resistant depression
- Jan 10, 2017- Innovative solution designed for blood and plasma screening maintains highest levels of accuracy while substantially increasing productivity
- Jan 10, 2017- Next generation of harmonized systems, combined with recently launched AlinIQ professional services, provide a unique solution to help labs and hospital systems achieve measurably better healthcare performance- The Alinity family delivers unprecedented integration in diagnostic testing to help solve the lab's most pressing challenges- New clinical chemistry and immunoassay technologies allow for cost-effective volume growth in a footprint half the size of Abbott's current diagnostic systems[1]- Error-proof design elements help prevent costly mistakes in the lab- Easy-to-use software, common across all Alinity systems, helps labs simplify training and manage strained staffing resources- Scalable system design enables labs to address current and future needs
